Compare ALGN & RVTY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALGN | RVTY |
|---|---|---|
| Founded | 1997 | 1937 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.2B | 9.9B |
| IPO Year | N/A | N/A |
| Metric | ALGN | RVTY |
|---|---|---|
| Price | $165.05 | $100.25 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 14 |
| Target Price | ★ $188.92 | $112.31 |
| AVG Volume (30 Days) | 1.6M | ★ 1.7M |
| Earning Date | 10-29-2025 | 01-30-2026 |
| Dividend Yield | N/A | ★ 0.28% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 5.16 | 1.99 |
| Revenue | ★ $3,982,622,000.00 | $2,813,367,000.00 |
| Revenue This Year | $2.58 | $5.33 |
| Revenue Next Year | $3.41 | $3.07 |
| P/E Ratio | ★ $32.05 | $50.39 |
| Revenue Growth | 0.56 | ★ 3.37 |
| 52 Week Low | $122.00 | $81.36 |
| 52 Week High | $241.29 | $128.29 |
| Indicator | ALGN | RVTY |
|---|---|---|
| Relative Strength Index (RSI) | 78.33 | 53.40 |
| Support Level | $144.00 | $98.73 |
| Resistance Level | $166.61 | $104.44 |
| Average True Range (ATR) | 4.66 | 3.04 |
| MACD | 1.60 | -0.19 |
| Stochastic Oscillator | 94.04 | 39.70 |
Align Technology is the leading manufacturer of clear aligners. Invisalign, its main product, was approved by the Food and Drug Administration in 1998 and has since dominated, controlling over 90% of the market. Invisalign can treat roughly 90% of all malocclusion cases (misaligned teeth), and there are over 230,000 Invisalign-trained dentists and orthodontists. In 2022, Invisalign treated over 2 million cases, or roughly 10% of all orthodontic cases for the year, and it has treated over 14 million patients since its launch. Align also sells intraoral scanners under the brand iTero, which captures digital impressions of patients' teeth and illustrates treatment plans. Over 85% of Invisalign cases are submitted by digital scans, and iTero scans make up over half of these scans.
Revvity provides instruments, tests, services, and software solutions to the pharmaceutical, biomedical, chemical, environmental, and general industrial markets. The company operates in two segments. First, its diagnostics segment includes immunodiagnostics, reproductive health, and applied genomics. Second, its discovery and analytical solutions is composed of life science, industrial, environmental, and food applications. Revvity offers products and services ranging from genetic screening and environmental analytical tools to informatics and enterprise software.